SANOFI news, videos and press releases
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Sanofi: Information concerning the total number of voting rights and shares – November 2024
- Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
- Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
- Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
- Sanofi: Information concerning the total number of voting rights and shares - October 2024
- Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
- Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
- Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
- Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
- Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
- Press Release: Availability of the Q3 2024 Aide mémoire
- Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
- Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
- Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
- Sanofi: Information concerning the total number of voting rights and shares - August 2024
- Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
- Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
- Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
- Sanofi: Information concerning the total number of voting rights and shares - July 2024
- Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
- Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
- Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
- Press Release: Availability of the Q2 2024 Aide-mémoire
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
- Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
- Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
- Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
- Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
- Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
- Sanofi: Information concerning the total number of voting rights and shares - March 2024
